151 related articles for article (PubMed ID: 25808119)
21. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor.
Abhyankar S; DeJarnette S; Aljitawi O; Ganguly S; Merkel D; McGuirk J
Bone Marrow Transplant; 2012 Apr; 47(4):483-7. PubMed ID: 21725372
[TBL] [Abstract][Full Text] [Related]
22. Comparison and cost analysis of three protocols for mobilization and apheresis of haematopoietic progenitor cells.
López-Castaño F; Manresa P; Díaz V; Arranz E; López J; Pérez M; Alda O; Hernández L
J Clin Apher; 2019 Aug; 34(4):461-467. PubMed ID: 30817045
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
Stover JT; Shaw JR; Kuchibhatla M; Horwitz ME; Engemann AM
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174
[TBL] [Abstract][Full Text] [Related]
24. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
Costa LJ; Kramer C; Hogan KR; Butcher CD; Littleton AL; Shoptaw KB; Kang Y; Stuart RK
Transfusion; 2012 Nov; 52(11):2375-81. PubMed ID: 22404694
[TBL] [Abstract][Full Text] [Related]
25. Who should be really considered as a poor mobilizer in the plerixafor era?
Andreola G; Vanazzi A; Radice D; Babic A; Rabascio C; Negri M; Martinelli G; Laszlo D
Transfus Apher Sci; 2012 Aug; 47(1):27-32. PubMed ID: 22480954
[TBL] [Abstract][Full Text] [Related]
26. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Veltri L; Cumpston A; Shillingburg A; Wen S; Luo J; Leadmon S; Watkins K; Craig M; Hamadani M; Kanate AS
Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754
[TBL] [Abstract][Full Text] [Related]
28. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E
Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584
[TBL] [Abstract][Full Text] [Related]
29. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
[TBL] [Abstract][Full Text] [Related]
30. [In vivo effect of rhG-CSF on the CXCR-4 expression of hematopoietic progenitor or stem cells in bone marrow and peripheral blood].
Zhao XY; Chang YJ; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):857-60. PubMed ID: 16277858
[TBL] [Abstract][Full Text] [Related]
31. The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.
Moreb JS; Lantos L; Chen F; Elliott K; Dugan J; Skarbnik AP; Kropf PL; Ward K
Transfus Apher Sci; 2023 Dec; 62(6):103787. PubMed ID: 37704508
[TBL] [Abstract][Full Text] [Related]
32. Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.
Sánchez-Ortega I; Querol S; Encuentra M; Ortega S; Serra A; Sanchez-Villegas JM; Grifols JR; Pujol-Balaguer MM; Pujol-Bosch M; Martí JM; Garcia-Cerecedo T; Barba P; Sancho JM; Esquirol A; Sierra J; Duarte RF
Bone Marrow Transplant; 2015 Jan; 50(1):34-9. PubMed ID: 25222503
[TBL] [Abstract][Full Text] [Related]
33. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.
Costa LJ; Miller AN; Alexander ET; Hogan KR; Shabbir M; Schaub C; Stuart RK
Bone Marrow Transplant; 2011 Apr; 46(4):523-8. PubMed ID: 20622909
[TBL] [Abstract][Full Text] [Related]
34. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfus Apher Sci; 2012 Jun; 46(3):257-62. PubMed ID: 22465758
[TBL] [Abstract][Full Text] [Related]
35. Use of plerixafor in patients with Hodgkin lymphoma with poor mobilization of peripheral blood stem cells.
Yuan S; Nademanee A; Forman SJ; Wang S
Leuk Lymphoma; 2013 Mar; 54(3):646-8. PubMed ID: 22812457
[No Abstract] [Full Text] [Related]
36. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P
J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277
[TBL] [Abstract][Full Text] [Related]
37. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
[TBL] [Abstract][Full Text] [Related]
38. Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield.
Villa CH; Shore T; Van Besien K; Cushing M
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1867-75. PubMed ID: 22796644
[TBL] [Abstract][Full Text] [Related]
39. Blood graft composition after plerixafor injection in patients with NHL.
Varmavuo V; Mäntymaa P; Nousiainen T; Valonen P; Kuittinen T; Jantunen E
Eur J Haematol; 2012 Aug; 89(2):128-35. PubMed ID: 22536949
[TBL] [Abstract][Full Text] [Related]
40. Impact of good and poor mobilizers on hematopoietic progenitor cell collection efficiency and product quality.
Azzouqa AM; Jouni K; Roy V; Zubair AC
J Clin Apher; 2019 Feb; 34(1):39-43. PubMed ID: 30426567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
